Skip to main content
Thank you for visiting nature.com. You are using a browser version
with limited support for CSS. To obtain the best experience, we
recommend you use a more up to date browser (or turn off
compatibility mode in Internet Explorer). In the meantime, to
ensure continued support, we are displaying the site without styles
and JavaScript.
Advertisement
[image]
[image]
•  View all journals
•  
Search
•  Log in
•  Content Explore content
•  About the journal
•  Publish with us
•  Subscribe
•  Sign up for alerts
•  RSS feed
1. nature 
2. bone marrow transplantation 
3. review 
4. article
Show authors
•  Review
•  Published: 31 March 2014


Autologous haematopoietic
stem cell mobilisation in
multiple myeloma and
lymphoma patients: a position
statement from the European
Group for Blood and Marrow
Transplantation
•  M Mohty
1 na1,
•  K Hübel2 na1,
•  N Kröger3 na1,
•  M Aljurf4 na1,
•  J Apperley5 na1,
•  G W Basak6 na1,
•  A Bazarbachi7 na1,
•  K Douglas8 na1,
•  I Gabriel5 na1,
•  L Garderet1 na1,
•  C Geraldes9 na1,
•  O Jaksic10 na1,
•  M W Kattan11 na1,
•  Z Koristek12 na1,
•  F Lanza13 na1,
•  R M Lemoli14 na1,
•  L Mendeleeva15 na1,
•  G Mikala16 na1,
•  N Mikhailova17 na1,
•  A Nagler18 na1,
•  H C Schouten19 na1,
•  D Selleslag20 na1,
•  S Suciu21 na1,
•  A Sureda22 na1,
•  N Worel23 na1,


•  P Wuchter24 na1,
•  C Chabannon25 na1 &
•  …
•  R F Duarte26 na1 
Bone Marrow Transplantation volume 49, pages 865–872 (2014)Cite
this article
•  10k Accesses
•  192 Citations
•  7 Altmetric
•  Metrics details
Subjects
•  Bone marrow transplantation
•  Haematological cancer
•  Therapeutics
Abstract
Autologous haematopoietic SCT with PBSCs is regularly used to
restore BM function in patients with multiple myeloma or
lymphoma after myeloablative chemotherapy. Twenty-eight experts
from the European Group for Blood and Marrow Transplantation
developed a position statement on the best approaches to
mobilising PBSCs and on possibilities of optimising graft yields in
patients who mobilise poorly. Choosing the appropriate
mobilisation regimen, based on patients’ disease stage and
condition, and optimising the apheresis protocol can improve
mobilisation outcomes. Several factors may influence mobilisation
outcomes, including older age, a more advanced disease stage, the
type of prior chemotherapy (e.g., fludarabine or melphalan), prior
irradiation or a higher number of prior treatment lines. The most
robust predictive factor for poor PBSC collection is the CD34+ cell
count in PB before apheresis. Determination of the CD34+ cell


count in PB before apheresis helps to identify patients at risk of
poor PBSC collection and allows pre-emptive intervention to rescue
mobilisation in these patients. Such a proactive approach might
help to overcome deficiencies in stem cell mobilisation and offers a
rationale for the use of novel mobilisation agents.
 Access through your institution
Buy or subscribe
This is a preview of subscription content, access via your institution
Access options
 Access through your institution
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Learn more
Buy this article
•  Purchase on SpringerLink
•  Instant access to full article PDF
Buy now
Prices may be subject to local taxes which are calculated during
checkout
Additional access options:
•  Log in
•  Learn about institutional subscriptions
•  Read our FAQs


•  Contact customer support
Figure 1
[image]
Figure 2
[image]
Figure 3
[image]
Similar content being viewed by others
[image]
Non-cryopreserved autologous peripheral blood stem
cell transplantation for multiple myeloma and
lymphoma in countries with limited resources:
practice considerations from the Worldwide Network
for Blood and Marrow Transplantation
Article 07 October 2024
[image]
Satisfactory outcomes following a second autologous
hematopoietic cell transplantation for multiple
myeloma in poor stem cell mobilizers: a retrospective
study on behalf of the Chronic Malignancies Working
Party of the EBMT
Article 12 November 2024
[image]
The immunome of mobilized peripheral blood stem
cells is predictive of long-term outcomes and therapy-
related myeloid neoplasms in patients with multiple
myeloma undergoing autologous stem cell transplant
Article Open access 26 September 2023


References
1. Gertz MA . Current status of stem cell mobilization. Br J
Haematol 2010; 150: 647–662.
CAS  PubMed  Google Scholar 
2. Mohty M, Ho AD . In and out of the niche: perspectives in
mobilization of hematopoietic stem cells. Exp Hematol 2011;
39: 723–729.
CAS  PubMed  Google Scholar 
3. Passweg JR, Baldomero H, Gratwohl A, Bregni M, Cesaro S,
Dreger P et al. The EBMT activity survey: 1990-2010. Bone
Marrow Transplant 2012; 47: 906–923.
CAS  PubMed  Google Scholar 
4. Vellenga E, van Agthoven M, Croockewit AJ, Verdonck LF,
Wijermans PJ, van Oers MH et al. Autologous peripheral
blood stem cell transplantation in patients with relapsed
lymphoma results in accelerated haematopoietic
reconstitution, improved quality of life and cost reduction
compared with bone marrow transplantation: the Hovon 22
study. Br J Haematol 2001; 114: 319–326.
CAS  PubMed  Google Scholar 
5. Vose JM, Sharp G, Chan WC, Nichols C, Loh K, Inwards D et
al. Autologous transplantation for aggressive non-Hodgkin's
lymphoma: results of a randomized trial evaluating graft
source and minimal residual disease. J Clin Oncol 2002; 20:
2344–2352.
PubMed  Google Scholar 
6. Pusic I, DiPersio JF . The use of growth factors in
hematopoietic stem cell transplantation. Curr Pharm Des
2008; 14: 1950–1961.


CAS  PubMed  Google Scholar 
7. Bensinger W, DiPersio JF, McCarty JM . Improving stem cell
mobilization strategies: future directions. Bone Marrow
Transplant 2009; 43: 181–195.
CAS  PubMed  Google Scholar 
8. Wuchter P, Ran D, Bruckner T, Schmitt T, Witzens-Harig M,
Neben K et al. Poor mobilization of hematopoietic stem cells-
definitions, incidence, risk factors, and impact on outcome of
autologous transplantation. Biol Blood Marrow Transplant
2010; 16: 490–499.
CAS  PubMed  Google Scholar 
9. Isidori A, Tani M, Bonifazi F, Zinzani P, Curti A, Motta MR et
al. Phase II study of a single pegfilgrastim injection as an
adjunct to chemotherapy to mobilize stem cells into the
peripheral blood of pretreated lymphoma patients.
Haematologica 2005; 90: 225–231.
CAS  PubMed  Google Scholar 
10. Putkonen M, Rauhala A, Pelliniemi TT, Remes K . Single-dose
pegfilgrastim is comparable to daily filgrastim in mobilizing
peripheral blood stem cells: a case-matched study in patients
with lymphoproliferative malignancies. Ann Hematol 2009;
88: 673–680.
PubMed  Google Scholar 
11. Russell N, Mesters R, Schubert J, Boogaerts M, Johnsen HE,
Canizo CD et al. A phase 2 pilot study of pegfilgrastim and
filgrastim for mobilizing peripheral blood progenitor cells in
patients with non-Hodgkin's lymphoma receiving
chemotherapy. Haematologica 2008; 93: 405–412.
CAS  PubMed  Google Scholar 
12. Tricot G, Barlogie B, Zangari M, van Rhee F, Hoering A,
Szymonifka J et al. Mobilization of peripheral blood stem cells


in myeloma with either pegfilgrastim or filgrastim following
chemotherapy. Haematologica 2008; 93: 1739–1742.
CAS  PubMed  Google Scholar 
13. Hart C, Grassinger J, Andreesen R, Hennemann B . EPO in
combination with G-CSF improves mobilization effectiveness
after chemotherapy with ifosfamide, epirubicin and etoposide
and reduces costs during mobilization and transplantation of
autologous hematopoietic progenitor cells. Bone Marrow
Transplant 2009; 43: 197–206.
CAS  PubMed  Google Scholar 
14. Johnsen HE, Geisler C, Juvonen E, Remes K, Juliusson G,
Hörnsten P et al. Priming with r-metHuSCF and filgrastim or
chemotherapy and filgrastim in patients with malignant
lymphomas: a randomized phase II pilot study of mobilization
and engraftment. Bone Marrow Transplant 2011; 46: 44–51.
CAS  PubMed  Google Scholar 
15. Lapierre V, Rossi JF, Heshmati F, Azar N, Vekhof A,
Makowski C et al. Ancestim (r-metHuSCF) plus filgrastim
and/or chemotherapy for mobilization of blood progenitors in
513 poorly mobilizing cancer patients: the French
compassionate experience. Bone Marrow Transplant 2011; 46:
936–942.
CAS  PubMed  Google Scholar 
16. DiPersio JF, Stadtmauer EA, Nademanee A, Micallef IN, Stiff
PJ, Kaufman JL et al. Plerixafor and G-CSF versus placebo and
G-CSF to mobilize hematopoietic stem cells for autologous
stem cell transplantation in patients with multiple myeloma.
Blood 2009; 113: 5720–5726.
CAS  PubMed  Google Scholar 
17. DiPersio JF, Micallef IN, Stiff PJ, Bolwell BJ, Maziarz RT,
Jacobsen E et al. Phase III prospective randomized double-
blind placebo-controlled trial of plerixafor plus granulocyte


colony-stimulating factor compared with placebo plus
granulocyte colony-stimulating factor for autologous stem-cell
mobilization and transplantation for patients with non-
Hodgkin's lymphoma. J Clin Oncol 2009; 27: 4767–4773.
CAS  PubMed  Google Scholar 
18. Jantunen E, Lemoli RM . Preemptive use of plerixafor in
difficult-to-mobilize patients: an emerging concept.
Transfusion 2012; 52: 906–914.
CAS  PubMed  Google Scholar 
19. Neupogen [Summary of Product Characteristics]. Amgen
Europe BV: Breda, The Netherlands, 2013. Available at:
www.medicines.org.uk/emc/medicine/27485/SPC/
Neupogen+30+MU+
%280.3+mg+ml%29+solution+for+injection/ (accessed
on 28 August 2013).
20. Granocyte [Summary of Product Characteristics]. Chugai
Pharma UK Ltd: London, UK, 1993. Available at:
www.medicines.org.uk/emc/medicine/8347/SPC/
Granocyte+13+million+IU%2c+and+34+million+IU/
(accessed on 28 August 2013).
21. Gertz MA, Kumar SK, Lacy MQ, Dispenzieri A, Hayman SR,
Buadi FK et al. Comparison of high-dose CY and growth factor
with growth factor alone for mobilization of stem cells for
transplantation in patients with multiple myeloma. Bone
Marrow Transplant 2009; 43: 619–625.
CAS  PubMed  Google Scholar 
22. Pusic I, Jiang SY, Landua S, Uy GL, Rettig MP, Cashen AF et
al. Impact of mobilization and remobilization strategies on
achieving sufficient stem cell yields for autologous
transplantation. Biol Blood Marrow Transplant 2008; 14:
1045–1056.
CAS  PubMed  Google Scholar 


23. Alegre A, Tomás JF, Martínez-Chamorro C, Gil-Fernández JJ,
Fernández-Villalta MJ, Arranz R et al. Comparison of
peripheral blood progenitor cell mobilization in patients with
multiple myeloma: high-dose cyclophosphamide plus GM-CSF
vs G-CSF alone. Bone Marrow Transplant 1997; 20: 211–217.
CAS  PubMed  Google Scholar 
24. Wood WA, Whitley J, Moore D, Sharf A, Irons R, Rao K et al.
Chemomobilization with etoposide is highly effective in
patients with multiple myeloma and overcomes the effects of
age and prior therapy. Biol Blood Marrow Transplant 2011; 17:
141–146.
CAS  PubMed  Google Scholar 
25. NCCN Clinical Practice Guidelines in Oncology (NCCN
Guidelines): Multiple Myeloma; version 2.2013. Available at:
http://www.nccn.org (accessed on 19 August 2013).
26. Desikan KR, Barlogie B, Jagannath S, Vesole DH, Siegel D,
Fassas A et al. Comparable engraftment kinetics following
peripheral-blood stem-cell infusion mobilized with
granulocyte colony-stimulating factor with or without
cyclophosphamide in multiple myeloma. J Clin Oncol 1998;
16: 1547–1553.
CAS  PubMed  Google Scholar 
27. Fox CP, McMillan AK, Bishton MJ, Haynes AP, Russell NH .
IVE (ifosfamide, epirubicin and etoposide) is a more effective
stem cell mobilisation regimen than ICE (ifosphamide,
carboplatin and etoposide) in the context of salvage therapy
for lymphoma. Br J Haematol 2008; 141: 244–248.
CAS  PubMed  Google Scholar 
28. Moskowitz CH, Bertino JR, Glassman JR, Hedrick EE, Hunte
S, Coady-Lyons N et al. Ifosfamide, carboplatin, and
etoposide: a highly effective cytoreduction and peripheral-
blood progenitor-cell mobilization regimen for transplant-


eligible patients with non-Hodgkin's lymphoma. J Clin Oncol
1999; 17: 3776–3785.
CAS  PubMed  Google Scholar 
29. Pavone V, Gaudio F, Guarini A, Perrone T, Zonno A, Curci P
et al. Mobilization of peripheral blood stem cells with high-
dose cyclophosphamide or the DHAP regimen plus G-CSF in
non-Hodgkin's lymphoma. Bone Marrow Transplant 2002; 29:
285–290.
CAS  PubMed  Google Scholar 
30. Watts MJ, Ings SJ, Leverett D, MacMillan A, Devereux S,
Goldstone AH et al. ESHAP and G-CSF is a superior blood
stem cell mobilizing regimen compared to cyclophosphamide
1.5 g m(-2) and G-CSF for pre-treated lymphoma patients: a
matched pairs analysis of 78 patients. Br J Cancer 2000; 82:
278–282.
CAS  PubMed  PubMed Central  Google Scholar 
31. Jantunen E . Novel strategies for blood stem cell mobilization:
special focus on plerixafor. Expert Opin Biol Ther 2011; 11:
1241–1248.
CAS  PubMed  Google Scholar 
32. Mozobil [Product Information]. Genzyme Ltd: Suffolk, UK,
2009. Available at: www.ema.europa.eu/docs/en_GB/
document_library/EPAR_-_Product_Information/
human/001030/WC500030686.pdf (accessed on 28 August
2013).
33. Attolico I, Pavone V, Ostuni A, Rossini B, Musso M,
Crescimanno A et al. Plerixafor added to chemotherapy plus
G-CSF is safe and allows adequate PBSC collection in
predicted poor mobilizer patients with multiple myeloma or
lymphoma. Biol Blood Marrow Transplant 2012; 18: 241–249.
CAS  PubMed  Google Scholar 


34. Basak GW, Jaksic O, Koristek Z, Mikala G, Basic-Kinda S,
Mayer J et al. Haematopoietic stem cell mobilization with
plerixafor and G-CSF in patients with multiple myeloma
transplanted with autologous stem cells. Eur J Haematol 2011;
86: 488–495.
CAS  PubMed  Google Scholar 
35. Cashen A, Lopez S, Gao F, Calandra G, MacFarland R, Badel K
et al. A phase II study of plerixafor (AMD3100) plus G-CSF for
autologous hematopoietic progenitor cell mobilization in
patients with Hodgkin lymphoma. Biol Blood Marrow
Transplant 2008; 14: 1253–1261.
CAS  PubMed  Google Scholar 
36. D’Addio A, Curti A, Worel N, Douglas K, Motta MR, Rizzi S et
al. The addition of plerixafor is safe and allows adequate
PBSC collection in multiple myeloma and lymphoma patients
poor mobilizers after chemotherapy and G-CSF. Bone Marrow
Transplant 2011; 46: 356–363.
PubMed  Google Scholar 
37. Dugan MJ, Maziarz RT, Bensinger WI, Nademanee A, Liesveld
J, Badel K et al. Safety and preliminary efficacy of plerixafor
(Mozobil) in combination with chemotherapy and G-CSF: an
open-label, multicenter, exploratory trial in patients with
multiple myeloma and non-Hodgkin's lymphoma undergoing
stem cell mobilization. Bone Marrow Transplant 2010; 45: 39–
47.
CAS  PubMed  Google Scholar 
38. Basak GW, Mikala G, Koristek Z, Jaksic O, Basic-Kinda S,
Cegledi A et al. Plerixafor to rescue failing chemotherapy-
based stem cell mobilization: it’s not too late. Leuk Lymphoma
2011; 52: 1711–1719.
CAS  PubMed  Google Scholar 
39. Calandra G, McCarty J, McGuirk J, Tricot G, Crocker SA,


Badel K et al. AMD3100 plus G-CSF can successfully mobilize
CD34+ cells from non-Hodgkin’s lymphoma, Hodgkin’s
disease and multiple myeloma patients previously failing
mobilization with chemotherapy and/or cytokine treatment:
compassionate use data. Bone Marrow Transplant 2008; 41:
331–338.
CAS  PubMed  Google Scholar 
40. Duarte RF, Shaw BE, Marín P, Kottaridis P, Ortiz M, Morante
C et al. Plerixafor plus granulocyte CSF can mobilize
hematopoietic stem cells from multiple myeloma and
lymphoma patients failing previous mobilization attempts: EU
compassionate use data. Bone Marrow Transplant 2011; 46:
52–58.
CAS  PubMed  Google Scholar 
41. Micallef IN, Stiff PJ, DiPersio JF, Maziarz RT, McCarty JM,
Bridger G et al. Successful stem cell remobilization using
plerixafor (mozobil) plus granulocyte colony-stimulating
factor in patients with non-hodgkin lymphoma: results from
the plerixafor NHL phase 3 study rescue protocol. Biol Blood
Marrow Transplant 2009; 15: 1578–1586.
CAS  PubMed  Google Scholar 
42. Carrión R, Serrano D, Gómez-Pineda A, Díez-Martín JL. A
randomised study of 10 microg/kg/day (single dose) vs 2 × 5
microg/kg/day (split dose) G-CSF as stem cell mobilisation
regimen in high-risk breast cancer patients. Bone Marrow
Transplant 2003; 32: 563–567.
PubMed  Google Scholar 
43. Romeo A, Chierichini A, Spagnoli A, Vittori M, Vacca M,
Gozzer M et al. Standard- versus high-dose lenograstim in
adults with hematologic malignancies for peripheral blood
progenitor cell mobilization. Transfusion 2010; 50: 2432–
2446.


PubMed  Google Scholar 
44. Nuamah NM, Goker H, Kilic YA, Dagmoura H, Cakmak A .
Spontaneous splenic rupture in a healthy allogeneic donor of
peripheral-blood stem cell following the administration of
granulocyte colony-stimulating factor (g-csf). A case report
and review of the literature. Haematologica 2006; 91: ECR08.
PubMed  Google Scholar 
45. Kim JE, Yoo C, Kim S, Lee DH, Kim SW, Lee JS et al. Optimal
timing of G-CSF administration for effective autologous stem
cell collection. Bone Marrow Transplant 2011; 46: 806–812.
CAS  PubMed  Google Scholar 
46. Micallef IN, Sinha S, Gastineau DA, Wolf R, Inwards DJ, Gertz
MA et al. Cost-effectiveness analysis of a risk-adapted
algorithm of plerixafor use for autologous peripheral blood
stem cell mobilization. Biol Blood Marrow Transplant 2013;
19: 87–93.
CAS  PubMed  Google Scholar 
47. Keeney M, Brown W, Gratama J, Papa S, Lanza F, Sutherland
DR et al. Single platform enumeration of viable CD34(pos)
cells. J Biol Regul Homeost Agents 2003; 17: 247–253.
CAS  PubMed  Google Scholar 
48. Whitby A, Whitby L, Fletcher M, Reilly JT, Sutherland DR,
Keeney M et al. ISHAGE protocol: are we doing it correctly?
Cytometry B 2012; 82: 9–17.
Google Scholar 
49. Abrahamsen JF, Stamnesfet S, Liseth K, Hervig T, Bruserud O
. Large-volume leukapheresis yields more viable CD34+ cells
and colony-forming units than normal-volume leukapheresis,
especially in patients who mobilize low numbers of CD34+
cells. Transfusion 2005; 45: 248–253.


CAS  PubMed  Google Scholar 
50. Coluccia P, Montefusco V, Tunesi S, Avella M, Bompadre A,
Longoni P et al. Peripheral blood stem cell collection in
multiple myeloma: a retrospective analysis of 6 years
leukapheresis activity in 109 patients treated at the Istituto
Nazionale dei Tumori of Milan. J Clin Apher 2009; 24: 134–
140.
PubMed  Google Scholar 
51. Jaksic O, Basic-Kinda S, Maricic I, Bojanic I, Nemet D, Pejsa V
et al. Effective stem cell mobilization with plerixafor+G-CSF
followed by large volume leukapheresis in poor mobilizers:
the experience of the Croatian cooperative group for
haematologic diseases (KROHEM). Bone Marrow Transplant
2010; 45: S321 (abstract P1018).
Google Scholar 
52. Donmez A, Tombuloglu M, Gungor A, Soyer N, Saydam G,
Cagirgan S . Clinical side effects during peripheral blood
progenitor cell infusion. Transfus Apher Sci 2007; 36: 95–101.
PubMed  Google Scholar 
53. Jiang L, Malik S, Litzow M, Gastineau D, Micallef I, Roy V et
al. Hematopoietic stem cells from poor and good mobilizers
are qualitatively equivalent. Transfusion 2012; 52: 542–548.
CAS  PubMed  Google Scholar 
54. Weaver CH, Hazelton B, Birch R, Palmer P, Allen C,
Schwartzberg L et al. An analysis of engraftment kinetics as a
function of the CD34 content of peripheral blood progenitor
cell collections in 692 patients after the administration of
myeloablative chemotherapy. Blood 1995; 86: 3961–3969.
CAS  PubMed  Google Scholar 
55. Holtan SG, Porrata LF, Micallef IN, Padley DJ, Inwards DJ,
Ansell SA et al. AMD3100 affects autograft lymphocyte


collection and progression-free survival after autologous stem
cell transplantation in non-Hodgkin lymphoma. Clin
Lymphoma Myeloma 2007; 7: 315–318.
CAS  PubMed  Google Scholar 
56. Fruehauf S, Veldwijk MR, Seeger T, Schubert M, Laufs S,
Topaly J et al. A combination of granulocyte-colony-
stimulating factor (G-CSF) and plerixafor mobilizes more
primitive peripheral blood progenitor cells than G-CSF alone:
results of a European phase II study. Cytotherapy 2009; 11:
992–1001.
CAS  PubMed  Google Scholar 
57. Taubert I, Saffrich R, Zepeda-Moreno A, Hellwig I, Eckstein V,
Bruckner T et al. Characterization of hematopoietic stem cell
subsets from patients with multiple myeloma after
mobilization with plerixafor. Cytotherapy 2011; 13: 459–466.
CAS  PubMed  Google Scholar 
58. Varmavuo V, Mäntymaa P, Silvennoinen R, Nousiainen T,
Kuittinen T, Jantunen E . CD34+ cell subclasses and
lymphocyte subsets in blood grafts collected after various
mobilization methods in myeloma patients. Transfusion 2013;
53: 1024–1032.
CAS  PubMed  Google Scholar 
59. Varmavuo V, Mäntymaa P, Kuittinen T, Nousiainen T,
Jantunen E . Blood graft lymphocyte subsets after plerixafor
injection in non-Hodgkin's lymphoma patients mobilizing
poorly with chemotherapy plus granulocyte-colony-
stimulating factor. Transfusion 2012; 52: 1785–1791.
CAS  PubMed  Google Scholar 
60. Porrata LF, Gastineau DA, Padley D, Bundy K, Markovic SN .
Re-infused autologous graft natural killer cells correlates with
absolute lymphocyte count recovery after autologous stem
cell transplantation. Leuk Lymphoma 2003; 44: 997–1000.


CAS  PubMed  Google Scholar 
61. Demirkazik A, Kessinger A, Armitage JO, Bierman PJ, Lynch
J, Vose J et al. Progenitor and lymphoma cells in blood stem
cell harvests: impact on survival following transplantation.
Bone Marrow Transplant 2001; 28: 207–212.
CAS  PubMed  Google Scholar 
62. DiPersio JF, Ho AD, Hanrahan J, Hsu FJ, Fruehauf S .
Relevance and clinical implications of tumor cell mobilization
in the autologous transplant setting. Biol Blood Marrow
Transplant 2011; 17: 943–955.
PubMed  Google Scholar 
63. Ho J, Yang L, Banihashemi B, Martin L, Halpenny M Atkins H
et al. Contaminating tumour cells in autologous PBSC grafts
do not influence survival or relapse following transplant for
multiple myeloma or B-cell non-Hodgkin's lymphoma. Bone
Marrow Transplant 2009; 43: 223–228.
CAS  PubMed  Google Scholar 
64. Kopp HG, Yildirim S, Weisel KC, Kanz L, Vogel W .
Contamination of autologous peripheral blood progenitor cell
grafts predicts overall survival after high-dose chemotherapy
in multiple myeloma. J Cancer Res Clin Oncol 2009; 135: 637–
642.
CAS  PubMed  Google Scholar 
65. Lemoli RM, Fortuna A, Motta MR, Rizzi S, Giudice V,
Nannetti A et al. Concomitant mobilization of plasma cells
and hematopoietic progenitors into peripheral blood of
multiple myeloma patients: positive selection and
transplantation of enriched CD34+ cells to remove
circulating myeloma cells. Blood 1996; 87: 1625–1634.
CAS  PubMed  Google Scholar 
66. Vogel W, Kopp HG, Kanz L, Einsele H . Myeloma cell


contamination of peripheral blood stem-cell grafts can predict
the outcome in multiple myeloma patients after high-dose
chemotherapy and autologous stem-cell transplantation. J
Cancer Res Clin Oncol 2005; 131: 214–218.
PubMed  Google Scholar 
67. Fruehauf S, Ehninger G, Hübel K, Topaly J, Goldschmidt H,
Ho AD et al. Mobilization of peripheral blood stem cells for
autologous transplant in non-Hodgkin's lymphoma and
multiple myeloma patients by plerixafor and G-CSF and
detection of tumor cell mobilization by PCR in multiple
myeloma patients. Bone Marrow Transplant 2010; 45: 269–
275.
CAS  PubMed  Google Scholar 
68. Tricot G, Cottler-Fox MH, Calandra G . Safety and efficacy
assessment of plerixafor in patients with multiple myeloma
proven or predicted to be poor mobilizers, including
assessment of tumor cell mobilization. Bone Marrow
Transplant 2010; 45: 63–68.
CAS  PubMed  Google Scholar 
69. Bourhis JH, Bouko Y, Koscielny S, Bakkus M, Greinix H,
Derigs G et al. Relapse risk after autologous transplantation in
patients with newly diagnosed myeloma is not related with
infused tumor cell load and the outcome is not improved by
CD34+ cell selection: long term follow-up of an EBMT phase
III randomized study. Haematologica 2007; 92: 1083–1090.
PubMed  Google Scholar 
70. Lemoli RM, Martinelli G, Zamagni E, Motta MR, Rizzi S,
Terragna C et al. Engraftment, clinical, and molecular follow-
up of patients with multiple myeloma who were reinfused
with highly purified CD34+ cells to support single or tandem
high-dose chemotherapy. Blood 2000; 95: 2234–2239.
CAS  PubMed  Google Scholar 


71. Stewart AK, Vescio R, Schiller G, Ballester O, Noga S, Rugo H
et al. Purging of autologous peripheral-blood stem cells using
CD34 selection does not improve overall or progression-free
survival after high-dose chemotherapy for multiple myeloma:
results of a multicenter randomized controlled trial. J Clin
Oncol 2001; 19: 3771–3779.
CAS  PubMed  Google Scholar 
72. Bashey A, Pérez WS, Zhang MJ, Anderson KC, Ballen K,
Berenson JR et al. Comparison of twin and autologous
transplants for multiple myeloma. Biol Blood Marrow
Transplant 2008; 14: 1118–1124.
PubMed  PubMed Central  Google Scholar 
73. Bierman PJ, Sweetenham JW, Loberiza FR Jr, Taghipour G,
Lazarus HM Rizzo JD et al. Syngeneic hematopoietic stem-cell
transplantation for non-Hodgkin's lymphoma: a comparison
with allogeneic and autologous transplantation—The
Lymphoma Working Committee of the International Bone
Marrow Transplant Registry and the European Group for
Blood and Marrow Transplantation. J Clin Oncol 2003; 21:
3744–3753.
PubMed  Google Scholar 
74. Eve HE, Seymour JF, Rule SA . Impairment of peripheral
blood stem-cell mobilisation in patients with mantle-cell
lymphoma following primary treatment with fludarabine and
cyclophosphamide +/− rituximab. Leuk Lymphoma 2009;
50: 463–465.
CAS  PubMed  Google Scholar 
75. Han X, Ma L, Zhao L, He X, Liu P, Zhou S et al. Predictive
factors for inadequate stem cell mobilization in Chinese
patients with NHL and HL: 14-year experience of a single-
center study. J Clin Apher 2012; 27: 64–74.
CAS  PubMed  Google Scholar 


76. Janikova A, Koristek Z, Vinklarkova J, Pavlik T, Sticha M,
Navratil M et al. Efficacious but insidious: a retrospective
analysis of fludarabine-induced myelotoxicity using long-term
culture-initiating cells in 100 follicular lymphoma patients.
Exp Hematol 2009; 37: 1266–1273.
CAS  PubMed  Google Scholar 
77. Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK,
Gastineau DA et al. Impact of lenalidomide therapy on stem
cell mobilization and engraftment post-peripheral blood stem
cell transplantation in patients with newly diagnosed
myeloma. Leukemia 2007; 21: 2035–2042.
CAS  PubMed  Google Scholar 
78. Mazumder A, Kaufman J, Niesvizky R, Lonial S, Vesole D,
Jagannath S . Effect of lenalidomide therapy on mobilization
of peripheral blood stem cells in previously untreated
multiple myeloma patients. Leukemia 2008; 22: 1280–1281.
CAS  PubMed  Google Scholar 
79. Mendrone A Jr, Arrais CA, Saboya R, Chamone Dde A, Dulley
FL . Factors affecting hematopoietic progenitor cell
mobilization: an analysis of 307 patients. Transfus Apher Sci
2008; 39: 187–192.
PubMed  Google Scholar 
80. Nakasone H, Kanda Y, Ueda T, Matsumoto K, Shimizu N,
Minami J et al. Retrospective comparison of mobilization
methods for autologous stem cell transplantation in multiple
myeloma. Am J Hematol 2009; 84: 809–814.
CAS  PubMed  Google Scholar 
81. Ozsan GH, Micallef IN, Dispenzieri A, Kumar S, Lacy MQ,
Dingli D et al. Hematopoietic recovery kinetics predicts for
poor CD34+ cell mobilization after cyclophosphamide
chemotherapy in multiple myeloma. Am J Hematol 2012; 87:
1–4.


CAS  PubMed  Google Scholar 
82. Paripati H, Stewart AK, Cabou S, Dueck A, Zepeda VJ, Pirooz
N et al. Compromised stem cell mobilization following
induction therapy with lenalidomide in myeloma. Leukemia
2008; 22: 1282–1284.
CAS  PubMed  Google Scholar 
83. Perseghin P, Terruzzi E, Dassi M, Baldini V, Parma M,
Coluccia P et al. Management of poor peripheral blood stem
cell mobilization: incidence, predictive factors, alternative
strategies and outcome. A retrospective analysis on 2177
patients from three major Italian institutions. Transfus Apher
Sci 2009; 41: 33–37.
PubMed  Google Scholar 
84. Popat U, Saliba R, Thandi R, Hosing C, Qazilbash M,
Anderlini P et al. Impairment of filgrastim-induced stem cell
mobilization after prior lenalidomide in patients with
multiple myeloma. Biol Blood Marrow Transplant 2009; 15:
718–723.
PubMed  PubMed Central  Google Scholar 
85. Sancho JM, Morgades M, Grifols JR, Juncà J, Guardia R,
Vives S et al. Predictive factors for poor peripheral blood stem
cell mobilization and peak CD34(+) cell count to guide pre-
emptive or immediate rescue mobilization. Cytotherapy 2012;
14: 823–829.
CAS  PubMed  Google Scholar 
86. Sinha S, Gastineau D, Micallef I, Hogan W, Ansell S, Buadi F
et al. Predicting PBSC harvest failure using circulating CD34
levels: developing target-based cutoff points for early
intervention. Bone Marrow Transplant 2011; 46: 943–949.
CAS  PubMed  Google Scholar 
87. Waterman J, Rybicki L, Bolwell B, Copelan E, Pohlman B,


Sweetenham J et al. Fludarabine as a risk factor for poor stem
cell harvest, treatment-related MDS and AML in follicular
lymphoma patients after autologous hematopoietic cell
transplantation. Bone Marrow Transplant 2012; 47: 488–493.
CAS  PubMed  Google Scholar 
88. Duarte R, Apperley JF, Basak G, Douglas K, Gabriel IH,
Geraldes C et al. Patient and disease characteristics
influencing the outcome of mobilization with plerixafor: large
compassionate-use analysis by ECOSM (European Consortium
for Stem Cell Mobilization). Bone Marrow Transplant 2011;
46: S60.
Google Scholar 
89. Copelan E, Pohlman B, Rybicki L, Kalaycio M, Sobecks R,
Andresen S et al. A randomized trial of etoposide and G-CSF
with or without rituximab for PBSC mobilization in B-cell
non-Hodgkin's lymphoma. Bone Marrow Transplant 2009; 43:
101–105.
CAS  PubMed  Google Scholar 
90. Cavallo F, Bringhen S, Milone G, Ben-Yehuda D, Nagler A,
Calabrese E et al. Stem cell mobilization in patients with
newly diagnosed multiple myeloma after lenalidomide
induction therapy. Leukemia 2011; 25: 1627–1631.
CAS  PubMed  Google Scholar 
91. Sinha S, Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR,
Buadi FK et al. Majority of patients receiving initial therapy
with lenalidomide-based regimens can be successfully
mobilized with appropriate mobilization strategies. Leukemia
2012; 26: 1119–1122.
CAS  PubMed  Google Scholar 
92. Mark T, Stern J, Furst JR, Jayabalan D, Zafar F, LaRow A et
al. Stem cell mobilization with cyclophosphamide overcomes
the suppressive effect of lenalidomide therapy on stem cell


collection in multiple myeloma. Biol Blood Marrow Transplant
2008; 14: 795–798.
CAS  PubMed  PubMed Central  Google Scholar 
93. Nazha A, Cook R, Vogl DT, Mangan PA, Gardler M, Hummel
K et al. Stem cell collection in patients with multiple
myeloma: impact of induction therapy and mobilization
regimen. Bone Marrow Transplant 2011; 46: 59–63.
CAS  PubMed  Google Scholar 
94. Lanza F, Lemoli RM, Olivieri A, Laszlo D, Martino M,
Specchia G et al. Factors affecting successful mobilization
with plerixafor: an Italian prospective survey in 215 patients
with multiple myeloma and lymphoma. Transfusion 2013; 54:
331–339.
PubMed  Google Scholar 
95. Abhyankar S, DeJarnette S, Aljitawi O, Ganguly S, Merkel D,
McGuirk J . A risk-based approach to optimize autologous
hematopoietic stem cell (HSC) collection with the use of
plerixafor. Bone Marrow Transplant 2012; 47: 483–487.
CAS  PubMed  Google Scholar 
96. Chen AI, Bains T, Murray S, Knight R, Shoop K, Bubalo J et al.
Clinical experience with a simple algorithm for plerixafor
utilization in autologous stem cell mobilization. Bone Marrow
Transplant 2012; 47: 1526–1529.
CAS  PubMed  Google Scholar 
97. Costa LJ, Alexander ET, Hogan KR, Schaub C, Fouts TV,
Stuart RK . Development and validation of a decision-making
algorithm to guide the use of plerixafor for autologous
hematopoietic stem cell mobilization. Bone Marrow Transplant
2011; 46: 64–69.
CAS  PubMed  Google Scholar 


98. Costa LJ, Miller AN, Alexander ET, Hogan KR, Shabbir M,
Schaub C et al. Growth factor and patient-adapted use of
plerixafor is superior to CY and growth factor for autologous
hematopoietic stem cells mobilization. Bone Marrow
Transplant 2011; 46: 523–528.
CAS  PubMed  Google Scholar 
99. Costa LJ, Abbas J, Hogan KR, Kramer C, McDonald K, Butcher
CD et al. Growth factor plus preemptive ('just-in-time')
plerixafor successfully mobilizes hematopoietic stem cells in
multiple myeloma patients despite prior lenalidomide
exposure. Bone Marrow Transplant 2012; 47: 1403–1408.
CAS  PubMed  Google Scholar 
100. Olivieri A, Marchetti M, Lemoli R, Tarella C, Iacone A, Lanza
F et al. Proposed definition of 'poor mobilizer' in lymphoma
and multiple myeloma: an analytic hierarchy process by ad
hoc working group Gruppo Italiano Trapianto di Midollo
Osseo. Bone Marrow Transplant 2012; 47: 342–351.
CAS  PubMed  Google Scholar 
Download references
Acknowledgements
Medical writing and editorial assistance was provided by Marianne
Jenal-Eyholzer, PhD, CMPP, from ETICHO (European Training in
Clinical Hematology and Oncology), The Hague, The Netherlands,
funded by an unrestricted grant from Sanofi. The authors are fully
responsible for the content of this manuscript.
Author information
Author notes


1. M Mohty, K Hübel, N Kröger, M Aljurf, J Apperley, G W
Basak, A Bazarbachi, K Douglas, I Gabriel, L Garderet, C
Geraldes, O Jaksic, M W Kattan, Z Koristek, F Lanza, R M
Lemoli, L Mendeleeva, G Mikala, N Mikhailova, A Nagler, H C
Schouten, D Selleslag, S Suciu, A Sureda, N Worel, P Wuchter,
C Chabannon and R F Duarte: All these authors contributed
equally to this work.
Authors and Affiliations
1. Department of Haematology, Saint Antoine Hospital, Paris,
France
M Mohty & L Garderet
2. University Hospital Cologne, Cologne, Germany
K Hübel
3. University Hospital Hamburg-Eppendorf, Hamburg, Germany
N Kröger
4. King Faisal Specialist Hospital and Research Centre, Riyadh,
Saudi Arabia
M Aljurf
5. Imperial College London, London, UK
J Apperley & I Gabriel
6. The Medical University of Warsaw, Warsaw, Poland
G W Basak
7. American University of Beirut, Beirut, Lebanon
A Bazarbachi
8. Beatson West of Scotland Cancer Centre, Glasgow, UK


K Douglas
9. University Hospital Coimbra, Coimbra, Portugal
C Geraldes
10. University Hospital Dubrava, Zagreb, Croatia
O Jaksic
11. Quantitative Health Sciences Cleveland Clinic, Cleveland, OH,
USA
M W Kattan
12. Department of Haematooncology, University Hospital
Ostrava, Ostrava, Czech Republic
Z Koristek
13. Cremona Hospital, Cremona, Italy
F Lanza
14. University of Genoa, Genoa, Italy
R M Lemoli
15. National Research Centre for Haematology, Moscow, Russia
L Mendeleeva
16. St Istvan and St Laszlo Hospital, Budapest, Hungary
G Mikala
17. Institute of Children Haematology and Transplantation n.a. R
Gorbacheva, St Petersburg State Pavlov Medical University,
St Petersburg, Russia
N Mikhailova
18. Chaim Sheba Medical Center, Tel, Hashomer, Israel


A Nagler
19. Maastricht University Medical Centre, Maastricht, The
Netherlands
H C Schouten
20. Department of Haematology, AZ Sint-Jan, Brugge-Oostende,
Belgium
D Selleslag
21. EORTC Headquarters, Brussels, Belgium
S Suciu
22. Addenbrooke's Hospital, Cambridge, UK
A Sureda
23. Medical University Vienna, Vienna, Austria
N Worel
24. Department of Medicine V, Heidelberg University,
Heidelberg, Germany
P Wuchter
25. Institut Paoli-Calmettes and Inserm CBT-510, Marseille,
France
C Chabannon
26. Catalan Institute of Oncology, L'Hospitalet de Llobregat,
Barcelona, Spain
R F Duarte
Authors
1. M Mohty
View author publications


Search author on:PubMed Google Scholar
2. K Hübel
View author publications
Search author on:PubMed Google Scholar
3. N Kröger
View author publications
Search author on:PubMed Google Scholar
4. M Aljurf
View author publications
Search author on:PubMed Google Scholar
5. J Apperley
View author publications
Search author on:PubMed Google Scholar
6. G W Basak
View author publications
Search author on:PubMed Google Scholar
7. A Bazarbachi
View author publications
Search author on:PubMed Google Scholar
8. K Douglas
View author publications
Search author on:PubMed Google Scholar
9. I Gabriel
View author publications
Search author on:PubMed Google Scholar
10. L Garderet


View author publications
Search author on:PubMed Google Scholar
11. C Geraldes
View author publications
Search author on:PubMed Google Scholar
12. O Jaksic
View author publications
Search author on:PubMed Google Scholar
13. M W Kattan
View author publications
Search author on:PubMed Google Scholar
14. Z Koristek
View author publications
Search author on:PubMed Google Scholar
15. F Lanza
View author publications
Search author on:PubMed Google Scholar
16. R M Lemoli
View author publications
Search author on:PubMed Google Scholar
17. L Mendeleeva
View author publications
Search author on:PubMed Google Scholar
18. G Mikala
View author publications
Search author on:PubMed Google Scholar


19. N Mikhailova
View author publications
Search author on:PubMed Google Scholar
20. A Nagler
View author publications
Search author on:PubMed Google Scholar
21. H C Schouten
View author publications
Search author on:PubMed Google Scholar
22. D Selleslag
View author publications
Search author on:PubMed Google Scholar
23. S Suciu
View author publications
Search author on:PubMed Google Scholar
24. A Sureda
View author publications
Search author on:PubMed Google Scholar
25. N Worel
View author publications
Search author on:PubMed Google Scholar
26. P Wuchter
View author publications
Search author on:PubMed Google Scholar
27. C Chabannon
View author publications


Search author on:PubMed Google Scholar
28. R F Duarte
View author publications
Search author on:PubMed Google Scholar
Corresponding author
Correspondence to M Mohty.
Ethics declarations
Competing interests
MM: Research support and honoraria from Sanofi, Amgen and
Chugai, whose products are discussed here. KH: Consulting fee or
honorarium and support for travel to meetings from Genzyme/
Sanofi; board membership for Pfizer and Noxxon; payment for
lectures including service on speakers’ bureaus from Janssen; and
travel/accommodations/meeting expenses unrelated to
activities listed from Roche. NK: Honorarium for lectures from
Sanofi; and consultant fee from Noxxon. MA: Consulting fee or
honorarium from ETICHO. GWB: Sponsorship for participation in
scientific conferences from Sanofi; membership of Mozobil advisory
boards for Sanofi; and reimbursements for trainings from Sanofi.
AB: Honoraria from Sanofi whose products are discussed here. KD:
Speaker’s fees and honoraria for medical advisory board work from
Genzyme and Sanofi Europe between 2009 and 2012 inclusive. GL:
Consulting fee or honorarium from ETICHO. CG: None disclosed.
OJ: Consulting fee or honorarium from ETICHO; and consultancy
for Sanofi. MWK: consultancy for GlaxoSmithKline, Bayer and
Merck. ZK: Consultancy for CEEOR; payment for lectures
including service on speakers’ bureaus from Sanofi-Aventis; and
travel/accommodations/meeting expenses unrelated to activities
listed from Sanofi-Aventis. RML: Payment for lectures including
service on speakers’ bureaus from Sanofi; and consultancy and
board membership for Sanofi. GM: Grant and fees for participation
in review activities such as data monitoring boards, statistical


analysis, end point committees and the like from ETICHO; support
for travel to meetings or other purposes from Genzyme; expert
testimony for Janssen and ETICHO; and payment for
lectures including service on speakers’ bureaus from Janssen. AN:
Research grant from Genzyme/Sanofi; and honorarium for
participating in a scientific advisory board. HCS: Membership of an
advisory board for Sanofi. DS: Honoraria and research grants from
Genzyme and Amgen; and membership of advisory boards for
Genzyme and Amgen. AS: Participation in Sanofi-organised
advisory boards. NW: Speaker’s fee from Sanofi and membership of
the advisory board. PW: Honorarium for lectures from Sanofi; and
consulting fee or honorarium from ETICHO. CC: Consultancy for
Terumo BCT, Novartis and Sanofi-Genzyme; and membership of an
advisory board for Sanofi-Genzyme. RFD: Consultancy for Sanofi-
Genzyme, Amgen and Italfarmaco; and payment for lectures
including service on speakers’ bureaus from Sanofi-Genzyme,
Amgen and Italfarmaco. JA, IG, FL, NM, LM and SS: no
relevant conflicts of interest.
Rights and permissions
Reprints and permissions
About this article
Cite this article
Mohty, M., Hübel, K., Kröger, N. et al. Autologous haematopoietic
stem cell mobilisation in multiple myeloma and lymphoma patients:
a position statement from the European Group for Blood and
Marrow Transplantation. Bone Marrow Transplant 49, 865–872
(2014). https://doi.org/10.1038/bmt.2014.39
Download citation
•  Received: 20 October 2013


•  Revised: 19 January 2014
•  Accepted: 28 January 2014
•  Published: 31 March 2014
•  Issue date: July 2014
•  DOI: https://doi.org/10.1038/bmt.2014.39
Share this article
Anyone you share the following link with will be able to read this
content:
Get shareable link
Sorry, a shareable link is not currently available for this article.
Copy shareable link to clipboard
Provided by the Springer Nature SharedIt content-sharing initiative
This article is cited by
•  Treosulfan plus fludarabine versus TEAM as
conditioning treatment before autologous stem
cell transplantation for B-cell Non-Hodgkin
lymphoma
○  Jochen J. Frietsch
○  Jenny Miethke
○  Inken Hilgendorf
Bone Marrow Transplantation (2022)
•  Disease Status at Transplant has a Significant
Impact on Outcomes of Autologous


Transplantation (ASCT) in Patients with Hodgkin
Lymphoma—A Single Center Experience
○  Jayastu Senapati
○  Anup J. Devasia
○  Biju George
Indian Journal of Hematology and Blood Transfusion (2022)
•  Chemotherapy-based versus chemotherapy-free
stem cell mobilization (± plerixafor) in multiple
myeloma patients: an Italian cost-effectiveness
analysis
○  Carlo Lazzaro
○  Luca Castagna
○  Riccardo Saccardi
Bone Marrow Transplantation (2021)
•  Implications of hematopoietic stem cells
heterogeneity for gene therapies
○  Jeremy Epah
○  Richard Schäfer
Gene Therapy (2021)
•  The association of mobilising regimen on
immune reconstitution and survival in myeloma
patients treated with bortezomib,
cyclophosphamide and dexamethasone induction
followed by a melphalan autograft
○  Matthew J. Rees
○  Peter Mollee
○  Andrew Grigg
Bone Marrow Transplantation (2021)


 Access through your institution
Buy or subscribe
Advertisement
[image]
Explore content
•  Research articles
•  Reviews & Analysis
•  News & Comment
•  Current issue
•  Collections
•  Follow us on Twitter
•  Subscribe
•  Sign up for alerts
•  RSS feed
About the journal
•  Journal Information
•  About the Editors
•  Contact
•  For Advertisers
•  Subscribe
•  Open Access Fees and Funding
Publish with us
•  For Authors and Referees
•  Language editing services


•  Open access funding
•  Submit manuscript
Search
Search articles by subject, keyword or author
Show results from All journals This journal
Search
Advanced search
Quick links
•  Explore articles by subject
•  Find a job
•  Guide to authors
•  Editorial policies
Bone Marrow Transplantation (Bone Marrow Transplant)
ISSN 1476-5365 (online)
ISSN 0268-3369 (print)
nature.com sitemap
About Nature Portfolio
•  About us
•  Press releases
•  Press office
•  Contact us
Discover content
•  Journals A-Z
•  Articles by subject
•  protocols.io


•  Nature Index
Publishing policies
•  Nature portfolio policies
•  Open access
Author & Researcher services
•  Reprints & permissions
•  Research data
•  Language editing
•  Scientific editing
•  Nature Masterclasses
•  Research Solutions
Libraries & institutions
•  Librarian service & tools
•  Librarian portal
•  Open research
•  Recommend to library
Advertising & partnerships
•  Advertising
•  Partnerships & Services
•  Media kits
•  Branded content
Professional development
•  Nature Awards
•  Nature Careers
•  Nature Conferences
Regional websites
•  Nature Africa


•  Nature China
•  Nature India
•  Nature Japan
•  Nature Middle East
•  Privacy Policy
•  Use of cookies
•  Your privacy choices/Manage cookies
•  Legal notice
•  Accessibility statement
•  Terms & Conditions
•  Your US state privacy rights
[image]
© 2025 Springer Nature Limited


[image]


